L3VLUP
ProSign in

ABCL in the 13F filings

Abcellera Biologics Inc · CUSIP 00288U106

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 13 Nov 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 3 listed it in both
Shares listed
34,835,218
combined, among listed positions
Reported value
$160m
combined, at the quarter end

Managers listing ABCL in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Baillie Gifford & Co26,204,649$121m0.11%Trimmed-160,10213 Nov 2023 (the filing on sec.gov)
Capital World Investors8,420,493$39munder 0.1%Held013 Nov 2023 (the filing on sec.gov)
PDT Partners LLC210,076$966k0.12%Added+125,61214 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q3 2024 to 2 in Q2 2026

Tracked managers listing it, at least.

02468202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ABCL by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20204$960mn.a.n.a.
Q1 20214$837mn.a.n.a.
Q2 20213$364mn.a.n.a.
Q3 20213$470mn.a.n.a.
Q4 20213$376mn.a.n.a.
Q1 20223$287mn.a.n.a.
Q2 20225$326mn.a.n.a.
Q3 20227$270mn.a.n.a.
Q4 20223$294mn.a.n.a.
Q1 20234$221mn.a.n.a.
Q2 20234$226mn.a.n.a.
Q3 20233$160mn.a.n.a.
Q4 20233$186m12
Q1 20243$144m11
Q2 20243$81m03
Q3 20241$34m02
Q4 20242$59m11
Q1 20252$55m11
Q2 20253$95m11
Q3 20255$147m40
Q4 20253$63m159
Q1 20261$47m912
Q2 20262$189m1213

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ABCL and LLY →ABCL and JNJ →ABCL and VRTX →Choose a stock to compare with ABCL →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ABCL, latest filings →Back to the 13F Explorer →